| Literature DB >> 26298540 |
M T van de Bilt1, C M Prado1, E P B Ojopi1, R T Sousa1, A A Loch1, M V Zanetti1, L L Talib1, W F Gattaz2.
Abstract
Evidence validating the influence of the cytochrome P450 (CYP) 2D6 and 2C19 enzymes genetic polymorphisms in the response to antipsychotics is scarce. We examined the hypothesis that a higher prevalence of CYP2D6 and/or CYP2C19 ultra rapid metabolizers might be found among refractory schizophrenia patients. Three groups were studied: refractory and non-refractory schizophrenia patients, and healthy controls. Participants were genotyped for CYP2D6 and CYP2C19 polymorphisms and classified in metabolic phenotypes. No between-group differences in the distribution of the phenotypes were found. Therefore, our findings do not support the CYPs 2D6 and 2C19 genotyping in the prediction of therapeutic response in schizophrenia.Entities:
Keywords: CYP enzymes; Pharmacogenetics; Refractoriness; Schizophrenia; Treatment
Mesh：
Substances：
Year: 2015 PMID： 26298540 DOI： 10.1016/j.schres.2015.08.002
Source DB: PubMed Journal: Schizophr Res ISSN： 0920-9964 Impact factor: 4.939